Sunita D. Nasta, MD, FACP
Professor of Clinical Medicine (Hematology-Oncology)
Attending Physician, Hospital of the University of Pennsylvania
Chair, Clinical Trials Scientific Research Monitoring Committee
Chair, Hospital University of Pennsylvania Credentialing Committee
Lymphoma Section Chief, Division of Hem/Onc
Department of Medicine
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-159
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-159
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-3933
Fax: 215-615-5887
Fax: 215-615-5887
Education:
BS (Microbiology & Immunology)
Stanford University, Palo Alto, CA , 1991.
MD
Medical College of Virginia, Richmond, VA, 1995.
Permanent linkBS (Microbiology & Immunology)
Stanford University, Palo Alto, CA , 1991.
MD
Medical College of Virginia, Richmond, VA, 1995.
Description of Research Expertise
Clinical trials in non-Hodgkin's lymphoma, phase I, II and IIIClinical trials in Castleman Diseaes
Description of Clinical Expertise
1.Management of patients with Non-Hodgkin's lymphoma, Hodgkin's Lymphoma, multiple myeloma, acute and chronic leukemias with standard therapy as well as clinical experimental therapies using new agents.2. Bone Marrow and Stem Cell Transplantation, autologous and allogeneic.
3. Special interest in treating patients with aggressive non-Hodgkin's lymphoma, lymphoma in the elderly and lymphoma in the pregnant patient.
4. Special interest in the long-term follow-up of patients with Hodgkin's lymphoma and survivors issues.
5. Management of patients with histiocytic disorders
6. Management of patients with Castleman disease.
Selected Publications
Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD.: Methotrexate-associated Peripheral Neuropathy on 18F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. Clin Nucl Med. Page: Online ahead of print. Apr 18 2025 Notes: doi: 10.1097/RLU.0000000000005899.Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatol. Page: e250251, Apr 2 2025 Notes: doi: 10.1001/jamadermatol.2025.0251.
Potluri VS, Zhang S, Schaubel DE, Shaikhouni S, Blumberg EA, Nasta SD, Bloom RD, Cruz-Peralta M, Mehta RB, Lavu NR, Getachew B, Tandukar S, Reese PP, Puttarajappa CM. : The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation : A Retrospective Cohort Study. Ann Intern Med. 178(2): 157-166, Feb 2025 Notes: doi: 10.7326/ANNALS-24-00165. Online ahead of print. PMID:
Stefan Barta, Stephen Schuster, Jakub Svoboda, Jordan Carter, Elise Chong, Daniel Landsburg, Sunita Nasta, Ruchi Patel, Joseph Fraietta, Colin Thomas, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Siciliano, Marco Ruella, Rosemary Mazanet: CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089. 2025 ASCO Annual Meeting June 2025 Notes: 10.1200/JCO.2025.43.16_suppl.TPS7087.
Saishravan Shyamsundar, Larissa Borys, Sheila Pierson, Mateo Sarmiento Bustamante, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan Lim, Gordan Srkalovic, Frits van Rhee, Sunita Nasta, Ariela Noy, Bridget Austin, Joshua Brandstadter, David Fajgenbaum: Variable response rates across chemotherapy regimens for severe idiopathic multicentric Castleman disease. 2025 ASCO Annual Meeting June 2025 Notes: 10.1200/JCO.2025.43.16_suppl.7082.
Nikita K. Dave, Paola Carvajal, Jordan S. Carter, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Daniel J. Landsburg, Sunita D. Nasta: Prolonged Methotrexate, Temozolomide and Rituximab in Secondary Central Nervous System Lymphoma 18-ICML abstract June 2025.
Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH.: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J Med. 392(18): 1824-1835, May 8 2025 Notes: doi: 10.1056/NEJMoa2408771.
Canty EA, Broderick L, Flaherty D, Xavier M, Nasta SD, Dajani L, White AA.: First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma. J Immunother Cancer. 13(4): e011092, Apr 1 2025 Notes: doi: 10.1136/jitc-2024-011092.
Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ.: Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP. Haematologica 110(4): 1023-1027, Apr 1 2025 Notes: doi: 10.3324/haematol.2024.286560. Epub
Pierson SK, Brandstadter JD, Torigian D, Bagg A, Lechowicz MJ, Alapat D MD, Casper C, Chadburn A, Chandrakasan S, Dispenzieri A, Fosså A, Hoffmann C, Ide M, Kurzrock R, Mukherjee S, Nasta SD, Navarro JT, Noy A, Oksenhendler E, Sarmiento Bustamante M, Shyamsundar S, Streetly MJ, Wong RSM, Zhang L, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC. : Characterizing the heterogeneity of Castleman disease and oligocentric subtype: Findings from the ACCELERATE registry. Blood Adv. Feb 14 2025 Notes: bloodadvances.2024014391. doi: 10.1182/bloodadvances.2024014391. Online ahead of print.